Kyowa Kirin begins phase 2 trial of ziftomenib in Japan for AML
Tweet Send to a Friend
Kyowa Kirin Co., Ltd. (TSE: 4151) and Kura Oncology, Inc. (NASDAQ: KURA) announced the first patient has been dosed in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


